RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30163% above fair value
$1.16−0.06 (-4.92%)
Close on Nov 12, 2026Market cap $52.35MP/E –Yield –
RenovoRx profit margin
Profit margin (net margin) is net income as a percentage of revenue.
RenovoRx's profit margin for the twelve months ending Sep 30, 2026 was -469.0%. For fiscal 2025 it was -994.5%, against -20497.7% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -994.5% | +19503.2 |
| FY2024 | Dec 31, 2024 | -20497.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -342.1% | +752.6 |
| Q2 FY2026 | Jun 30, 2026 | -320.2% | +365.8 |
| Q1 FY2026 | Mar 31, 2026 | -625.4% | +603.0 |
| Q4 FY2025 | Dec 31, 2025 | -1235.7% | – |
| Q3 FY2025 | Sep 30, 2025 | -1094.7% | – |
| Q2 FY2025 | Jun 30, 2025 | -686.0% | – |
| Q1 FY2025 | Mar 31, 2025 | -1228.4% | – |
See a number that looks wrong?